Skip to main content

Petros Pharmaceuticals, Inc.

PTPI
Exchange
OTC
Industry
Pharmaceutical Preparations
SEC CIK
0001815903

No open-market purchases or sales by Petros Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.

Q4 2022 vs. Q3 2022

How the institutions holding Petros Pharmaceuticals, Inc. changed between Q3 2022 and Q4 2022.

All holders in Q4 2022All holders in Q3 2022

13F holders of PTPI: Q3 2022 compared with Q4 2022
MeasureQ3 2022Q4 2022Change
Holders1310−3
Shares693.9K39.1K−654.9K (−94.4%)
Value$355.0K$90.6K−$264.4K (−74.5%)

New holders (3)

Institutions that held Petros Pharmaceuticals, Inc. at the end of Q4 2022 but not at the end of Q3 2022.

Institutions new to PTPI in Q4 2022
InstitutionSharesValue% of portfolio
UBS Group AG1,098$2.56K0.00%
Tower Research Capital LLC (TRC)503$1.00K0.00%
Bank of America Corp2$40.00%

Sold out (6)

Institutions that held Petros Pharmaceuticals, Inc. at the end of Q3 2022 and filed for Q4 2022 without it.

Institutions that sold out of PTPI in Q4 2022
InstitutionShares, Q3 2022Value, Q3 2022
Citadel Advisors LLC87,320$45.0K
Geode Capital Management, LLC76,654$39.0K
State Street Corp45,439$23.0K
Jane Street Group, LLC32,813$17.0K
Susquehanna International Group, LLP17,997$9.00K
Newbridge Financial Services Group, Inc.1,200$1.00K